Nov 4, 2021
Strategic Cooperation Agreement Between Amador Bioscience and Belgian Government
Amador Biotech signed a strategic cooperation with the Belgian government. Tom Vandeput, Deputy Governor of Limburg Province in Belgium, and Bernard Vanheusden, President of Hasselt University, attended the meeting.
\
Recently, Amador Biotech signed a strategic cooperation with the Belgian government. Tom Vandeput, Deputy Governor of Limburg Province in Belgium, and Bernard Vanheusden, President of Hasselt University, attended the meeting. Dr. Bing Wang, Chairman of Amador Bioscience, Xiaomin Chen, General Manager, and Zeng Rong, Chief Operating Officer, attended the event.
The European base will be set up in the new Health Campus in Limburg. Tom Vandeput, Deputy Governor of Limburg, said: “Located in the heart of Europe, Limburg has a unique position to integrate life sciences and high-tech industries. We are developing the campus into a global life sciences innovation hub, Amador Bioscience’s arrival will accelerate this process, and we give great importance to the arrival of this innovative company.”
Europe is playing an increasingly important role in the development of newly global drug R&D companies. Its investment in new drug R&D has increased rapidly, approaching the level of US R&D investment.
Amador already has a solid foundation in China and the United States. In the three years since its establishment, it has helped dozens of drug R&D companies complete hundreds of projects, covering macromolecular drugs, monoclonal antibodies, double-antibodies, ADCs, peptides, targeted small-molecule drugs, chemotherapy, etc., and successfully supported the market application of more than a dozen projects.
Accelerated global expansion
“Belgium has always been a promoter of European integration and is one of the founding and initial member states of the European Union. Belgium is the ideal gateway for Amador’s global expansion into Europe. We have just supported a leading European-based immuno-oncology company in the completion of a US BLA submission,” said Dr. Bing Wang.
“In the future, Amador Bioscience Europe will not only play a major role in the further European market expansion. We will also cooperate with Hasselt University to build a talent training program in drug research and development, and establish a joint venture with a local clinical trial center to provide global biopharmaceuticals. Companies build bridges to the European market.”
"We will establish branches in more drug innovation and R&D hubs around the world."
The Amador Bioscience Shanghai Office opened last month. Before that, the expansion plans of two bioanalytical labs were set in motion. As part of the global development strategy, the plans are to continue to increase investments in Europe in the next 2-3 years.
“We have already launched and expanded in the two largest markets in the world, the United States and China, and we will continue to expand in the future. Building upon our pharma R&D experience accumulated in Amgen, Novartis, and AstraZeneca in the past two decades. We will provide global translational science and clinical pharmacology services,” said Dr. Bing Wang.
